Skip to main content

Table 3 Patient characteristics - knee

From: Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis

Study, Year Number of patients TXA/C Gender distribution % male TXA /C Mean age TXA,C (SD or range) Mean weight (kg) - TXA, C (SD or Range) TBL - TXA,C (mL) (SD) P Value Number of patients requiring allogeneic transfusions (TXA, C) P Value
  TXA C TXA X TXA C TXA X TCA C   TXA C  
Hiippala, 1995[27] 15 13 13 23 70 (56–82) 70 (63–78) 72 (10) 74 (10) 847 (356) 1549 (574) <0.001 10 12 N/R
Benoni, 1996[17] 43 43 30 23 76 (7) 74 (7) 73 (14) 78 (16) 730 (280) 1410 (480) <0.001 8 24 <0.001
Hiippala, 1997[12] 39 38 10 21 70 (7) 69 (5) 74 (13) 78 (12) 689 (289) 1509 (643) < 0.0001 17 34 <0.0001
Jansen, 1999[2] 21 21 24 14 70.7 (62–80) 71.0 (64–84) 78.8 (11.0) 75.8 (12.4) 678 (352) 1419 (607) <0.001 2 13 <0.001
Engel, 2001[42] 12 12 50 50 71 (9) 66 (11) 83 (12) 80 (13) 800 (295–1050) 865 (245–1370) N/R 0 3 N/R
Ellis, 2001[36] 10 10 40 30 71 (5) 72 (8) 80 (12) 77 (15) N/R N/R N/R 1 7 N/R
Tanaka, 2001[41] ** 73 26 29, 32, 30   65 (59–70), , 65 (60–71), 65 (59–69) 65 (58–70) 60 (45–70), 60 (45–70), 60 (40–76) 61 (45 to 76) 720.4* (187.2) 1470 (264.8) N/R 17, 16, 14 26 N/R
Veien, 2002[3] 15 15 73 93 70.5 (9.5) 69.5 (9.0) 78.7 (12.3) 74.3 (14.1) 409.7 (174.9) 761.7 (313.1) <0.001 0 2 N/R
Good, 2003[18] 27 24 33 25 72 (46–83) 72 (50–84) 79 (13) 80 (13) 1045 (368.7 ) 1426 (620.9 ) <0.001 3 14 <0.001
Zohar, 2004[35] *** 60 20 30, 20, 40 35 73 (8), 69 (7), 69 (10) 73 (7) 78 (12), 75 (13), 77 (13) 75 (12) N/R N/R N/R 3, 2, 4 12 N/R
Orpen, 2006[5] 15 14 47 79 73 (95% CI 70–78) 69 (95% CI 63–74) 83 (95% CI 69–112) 77 (95% CI 58–96) 660 (317.6)† 726 (333.0) † 0.55 1 3 N/R
Camarasa, 2006[31] 35 60 26 20 73 (61–84) 72 (52–85) N/R 1095 (473) 1784 (660) N/R N/R N/R
Álvarez, 2007[6] 46 49 15 20 71 (9) 72 (7) N/R 1301 (621) 1744 (804) 0.002 N/R N/R
Molloy, 2007[19] 50 50 N/R N/R N/R N/R N/R 1225 (499) 1415 (416) 0.041 5 11 0.79
Kakar 2009[4]‡ 12 12 25 33 62.4 (9.4), 66.2 (4.8) 67.9 (10.8) 63.4 (7.2) 160 (87) 270 (88) <0.05 N/R N/R
Wong, 2010[11] □ 64 35 19, 42 □ 37 67 (11.9), 63.9 (10.6) 68.4 (10.4) 82.0 (15.6), 81.8 (14.7) 87.9 (19.2) 1295 (353.7), 1208 (376.0) 1610 (378.6) 0.0001 1, 0 2 0.083
Ishida, 2011[43] 50 50 12 12 73.3 (5.0) 73.5 (6.1) 59.7 (9.0) 59.7 (10.1) N/R N/R 0 1 N/R
Sa-ngasoongsong, 2011[24] 24 24 78 82 69.0 (8.2) 69.2 (7.6) N/R N/R 206.3 (115.4) 385.1 (145.2) <0.0001° 1 8 0.023
Roy, 2012[37] 25 25 40 36 66.04 (7.15) 66.56 (8.03) N/R N/R **** 109.6 ± 71.54 + 401 ± 82.44 **** 194 ± 79.66 + 870 ± 201.04 N/R 2 7 Not Significant
  1. * - Weighted Mean Value7, † - Calculated from 95% CI, § Average, SD – Standard Deviation, C – Control group, TXA – Tranexamic acid group, - Median Value, DVT – deep venous thrombosis, ** (Patients received pre-op TXA, patients received intra-op TXA, patients received both pre + intra op TXA), ‡ - Unilateral TKA data reported only, □ - (Patients received 1.5 gm TXA, patients received 3 gm TXA), *** (Patients received TXA bolus + long IV, patients received TXA bolus + short IV, patients received oral TXA), N/R – not reported. **** Sum of per-operative and drain collection. ↑Patients received TXA prior to tourniquet deflation, an additional preoperative dose, an additional postoperative dose, all three doses, or locally.